Pascal Soriot, AstraZeneca CEO (Justin Tallis/Press Association via AP Images)
July 29, 2024 07:19 AM EDTUpdated 11:09 AM
R&D

As­traZeneca’s fixed-du­ra­tion Calquence com­bo suc­ceeds in Phase 3 blood can­cer test

Ayisha Sharma

News Reporter

When giv­en with oth­er can­cer drugs for a lim­it­ed time, As­traZeneca’s Calquence hit the pri­ma­ry end­point in a reg­is­tra­tional test, which could open up a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times